文献速递MDS 与骨髓增殖性肿瘤白血病

恶性肿瘤继发的治疗相关骨髓增生异常综合征和急性髓系白血病患者的临床特征与预后

[Clinical characteristics and prognosis of patients with therapy-related myelodysplastic syndrome and acute myeloid leukemia arising from malignant tumors].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2023-01-01

回顾性分析四川大学华西医院2010年1月至2023年4月86例肿瘤治疗相关骨髓增生异常综合征和急性髓系白血病(t-MDS/AML)患者,原发肿瘤以乳腺癌、肠癌常见,不良遗传学风险较高;急性早幼粒细胞白血病(APL)诱导缓解率高、长期预后好,非APL患者缓解率低、预后不良。

要点

  • 原发肿瘤以乳腺癌(27.9%)、肠癌(17.4%)等多见,不良遗传学风险较高。
  • APL患者按原发初治方案治疗,1年OS率100.0%,中位OS未达到。
  • 非APL的t-AML首次诱导化疗完全缓解率30.8%,缓解者中位OS长于未缓解者。

核心结论

  • 乳腺癌、肠癌等原发肿瘤在t-MDS/AML中常见,具有较高的不良遗传学风险。
  • APL患者诱导缓解率高、长期预后较好,非APL患者缓解率低且预后不良。

研究设计与样本

  • 回顾性分析2010年1月至2023年4月四川大学华西医院86例肿瘤t-MDS/AML患者临床资料,分析临床特征、分子生物学特点、治疗及生存情况。

主要发现

  • 62例可遗传学分层:低危20例(29.9%)中位OS 36(95%CI 22~52)个月,中危10例(14.9%)6(95%CI 3~9)个月,高危32例(47.8%)8(95%CI 1~15)个月。
  • 非低危组t-AML中位OS 8(95%CI 3~13)个月,短于低危组(χ²=13.856,P<0.001);非APL的t-AML低危组中位OS 27(95%CI 18~36)个月,长于非低危组(Breslow χ²=5.534,P=0.019)。
  • 9例APL均按原发初治APL诱导维持治疗,中位OS未达到,1、2、3年OS率分别为100.0%、(75.0±6.2)%、(75.0±6.2)%。
  • 58例非APL的t-AML中52例(89.7%)接受化疗,首次诱导化疗完全缓解16例(30.8%);1、2、3年OS率分别为(42.0±6.6)%、(22.9±5.7)%、(13.4±4.7)%。
  • 化疗达骨髓缓解者中位OS 24(95%CI 18~30)个月,长于未缓解者6(95%CI 3~9)个月(χ²=6.087,P=0.014);13例含维奈克拉方案骨髓CR 7例(53.8%),中位OS 12(95%CI 9~15)个月,与不含维奈克拉方案差异无统计学意义(χ²=2.343,P=0.126)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To investigate the clinical characteristics, cytogenetics, molecular biology, treatment, and prognosis of patients with therapy-related myelodysplastic syndrome and acute myeloid leukemia (t-MDS/AML) secondary to malignancies. Methods: The clinical data of 86 patients with t-MDS/AML in West China Hospital of Sichuan University between January 2010 and April 2023 were retrospectively analyzed. The clinical characteristics, primary tumor types, and tumor-related therapies were analyzed. Results: The study enrolled a total of 86 patients with t-MDS/AML, including 67 patients with t-AML, including 1 patient with M(0), 6 with M(1), 27 with M(2), 9 with M(3), 12 with M(4), 10 with M(5), 1 with M(6), and 1 with M(7). Sixty-two patients could be genetically stratified, with a median overall survival (OS) of 36 (95% CI 22-52) months for 20 (29.9%) patients in the low-risk group and 6 (95% CI 3-9) months for 10 (14.9%) in the intermediate-risk group. The median OS time was 8 (95% CI 1-15) months in 32 (47.8%) patients in the high-risk group. For patients with non-acute promyelocytic leukemia (APL) and AML, the median OS of the low-risk group was 27 (95% CI 18-36) months, which was significantly longer than that of the non-low-risk group (χ(2)=5.534, P=0.019). All 9 APL cases were treated according to the initial treatment, and the median OS was not reached, and the 1-, 2-, and 3-year OS rates were 100.0%, (75.0±6.2) %, and (75.0±6.2) % respectively. Of the 58 patients with non-APL t-AML (89.7%), 52 received chemotherapy, and 16 achieved complete remission (30.8%) after the first induction chemotherapy. The 1-, 2-, and 3-year OS rates of the non-APL t-AML group were (42.0 ± 6.6) %, (22.9±5.7) %, and (13.4±4.7) %, respectively. The median OS of patients who achieved remission was 24 (95% CI 18-30) months, and the median OS of those who did not achieve remission was 6 (95% CI 3-9) months (χ(2)=10.170, P=0.001). Bone marrow CR was achieved in 7 (53.8%) of 13 patients treated with vineclar-containing chemotherapy, with a median OS of 12 (95% CI 9-15) months, which was not significantly different from that of vineclar-containing chemotherapy (χ(2)=0.600, P=0.437). In 19 patients with t-MDS, the 1-, 2-, and 3-year OS rates were (46.8±11.6) %, (17.5±9.1) %, and (11.7±9.1) % with a median OS of 12 (95% CI 7-17) months, which was not significantly different from that in t-AML (χ(2)=0.232, P=0.630) . Conclusions: Breast cancer, bowel cancer, and other primary tumors are common in patients with t-MDS/AML, which have a higher risk of adverse genetics. Patients with APL had a high induction remission rate and a good long-term prognosis, whereas patients without APL had a low remission rate and a poor long-term prognosis. 目的: 探讨肿瘤治疗相关骨髓增生异常综合征和急性髓系白血病(t-MDS/AML)的临床特征、分子生物学特点、疗效以及预后。 方法: 回顾性分析2010年1月至2023年4月四川大学华西医院86例肿瘤t-MDS/AML患者临床资料,分析肿瘤t-MDS/AML患者的临床特征、分子生物学特点、治疗及其生存情况。 结果: 研究共纳入86例肿瘤t-MDS/AML患者,原发肿瘤类型主要包括乳腺癌(27.9%)、肠癌(17.4%)、淋巴瘤(12.8%)、肺癌(11.6%)。t-AML患者67例,其中M(0) 1例、M(1) 6例、M(2) 27例、M(3) 9例、M(4) 12例、M(5) 10例、M(6) 1例、M(7) 1例。62例患者可进行遗传学分层,20例(29.9%)低危组患者中位总生存(OS)时间为36(95%CI 22~52)个月;10例(14.9%)中危组患者中位OS时间为6(95%CI 3~9)个月;32例(47.8%)高危患者中位OS时间为8(95%CI 1~15)个月。非低危组t-AML患者中位OS时间为8(95%CI 3~13)个月,明显短于低危组(χ(2)=13.856,P<0.001);非急性早幼粒细胞白血病(APL)的t-AML低危组患者中位OS时间为27(95%CI 18~36)个月,长于非低危组(Breslow,χ(2)=5.534,P=0.019),尤其早期OS率差异显著。9例APL病例均按照原发初治APL诱导维持治疗,中位OS时间未达到,1、2、3年OS率分别为100.0%、(75.0±6.2)%、(75.0±6.2)%。58例非APL的t-AML患者中,52例(89.7%)接受化疗,首次诱导化疗完全缓解16例(30.8%)。非APL的t-AML患者的1、2、3年OS率分别为(42.0±6.6)%、(22.9±5.7)%、(13.4±4.7)%。经化疗达到骨髓缓解的患者中位OS时间显著长于未能缓解的患者24(95%CI 18~30)个月对6(95%CI 3~9)个月,(χ(2)=6.087,P=0.014)。13例患者使用含维奈克拉方案化疗骨髓CR 7例(53.8%),中位OS时间为12(95%CI 9~15)个月,和不含维奈克拉方案化疗对比差异无统计学意义(χ(2)=2.343,P=0.126)。19例t-MDS患者中,1、2、3年OS率分别为(46.8±11.6)%、(17.5±9.1)%、(11.7±9.1)%,中位OS时间为12(95%CI 7~17)个月,与t-AML相比差异无统计学意义(χ(2)=0.656,P=0.418)。 结论: 临床上t-MDS/AML的原发肿瘤为乳腺癌、肠癌等较为常见,具有较高的不良遗传学风险。其中APL患者的诱导缓解率高、长期预后较好,非APL患者缓解率低且预后不良。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Xu XS, Ding H, Zhang X, et al. [Clinical characteristics and prognosis of patients with therapy-related myelodysplastic syndrome and acute myeloid leukemia arising from malignant tumors]. Zhonghua Xue Ye Xue Za Zhi. 2023. PMID: 38049318. doi:10.3760/cma.j.issn.0253-2727.2023.09.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。